Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines

ESMO-Magnitude of Clinical Benefit Scale

ESMO MCBS 1000x250

What is the ESMO-MCBS?

The ESMO-MCBS facilitates improved decision-making regarding the value of anti-cancer therapies, promotes accessibility and reduces iniquity of access to high value cancer treatments.

Read more

Accessibility and Availability of Medicines

Discover ESMO works to ensure access to and the availability of medicines so that cancer patients receive the best possible treatment available

Read more
ESMO-MCBS for Solid Tumours

ESMO-MCBS for Solid Tumours

Check out the forms and instructions of ESMO-MCBS for solid tumours and discover the cancer medicines that have been scored and published by ESMO

Read more

Dissemination and applicability of the ESMO-MCBS

Keep up to date with the latest ESMO publications and Congress presentations of the ESMO-MCBS and make sure you don’t miss anything!

  1. Special Session, ESMO-MCBS: What have we learnt and how can we expand?
  2. Poster Discussion Session - Public policy, 1631PD_PR - Clinical benefit and prices of cancer drugs in the US and Europe
  3. Educational Session, Surviving a cancer diagnosis with a good QoL
  4. Proffered paper session - Public policy, 1626O - ESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?
  5. Proffered paper session - Public policy, 1627O - Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015
  6. Proffered paper session - Public policy, 1628O - Consistency of ESMO-MCBS scores with drug access recommendations in Catalonia
  1. Special Session
  2. Poster Discussion Session - Public health policy, 1562PD - Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA)
  3. Poster Discussion Session - Public health policy, 1563PD - Magnitude of Clinical Benefit in Trials Supporting US Food and Drug Administration (FDA) Accelerated Approval (AA) and European Medicines Agency (EMA) Conditional Marketing Authorisation (CMA) and Subsequent Trials Supporting Conversion to Full Approval
  4. Poster Discussion Session - Public health policy, 1564PD - Magnitude of Clinical Benefit of Trials Supporting US Food and Drug Administration (FDA) Approval of Breakthrough and Non-breakthrough Drugs
  5. Poster Discussion Session - Public health policy, 1565PD - Time to access to novel anticancer therapies in Slovenia in view of the ESMO-MCBS scores
  6. Proffered paper session - Public health policy, 1555O_PR - Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe
  1. 1441PD - Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours
  2. Special Session, Cost, value and assessment tools of therapies in modern oncology
  3. Proffered Paper Session: 1435O_PR - Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in Clinical Trials Supporting US Food and Drug Administration (FDA) Approval of Orphan vs. Non-orphan Drugs.
  4. Proffered Paper Session: 1436O_PR - How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS
  5. Proffered Paper Session: 1437O_PR - Clinical Benefit of Randomized Controlled Trials (RCT) Supporting US Food and Drug Administration (FDA) Conversion from Accelerated to Full Approval
  1. Special Session: ESMO-MCBS and other scales to grade drugs
  1. Abstract 1511P: TKIs in first-line for advanced NSCLC with activating EGFR-mutations: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized controlled trials
  2. Abstract: 1365PD Do contemporary randomized controlled trials meet ESMO thresholds for clinically meaningful benefit?
  3. Special Session, Clinical benefit of Cancer Drugs
  4. Special Symposium, ESMO’s initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing in the magnitude of clinical benefit
  5. Proffered Paper Session: Abstract 1364O: The ESMO-Magnitude of Clinical Benefit Scale (MCBS) in rare tumor entities: A real life experience at the Medical University Vienna
  1. Special Session: Resource constraints as a barrier to lung cancer management
  1. ESMO Society Session (28 September), where Elisabeth de Vries presented the scale and Alexandru Eniu  explained how the scale is applied using the data from the ESMO Anti-Neoplastic Medicines Surveys.
  2. ESO Society Session: ‘Is innovation Affordable?’, 26 September
  3. Oncopolicy Forum: Inequalities in Treatment Outcomes, 27 September
  4. Special Session: Evaluating Clinical Benefit of Cancer Drugs Across Tumours, 28 September

ASCO 2015: ESMO-MCBS was launched at the ESMO/ASCO Joint Session during ASCO 2015

In this podcast, Professor Martine Piccart (Scientific Director of the Institut Jules Bordet, Universite Libre de Bruxelles, Belgium) shares valuable insights on the work that has been done in the field of access to essential cancer medicines by the ESMO-Magnitude of Clinical Benefit Scale Working Group

For further information about the ESMO-MCBS, please send an email to mcbs@esmo.org

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.